» Articles » PMID: 29465575

Impact of Vitamin D Receptor and Binding Protein Gene Polymorphisms in Clinical and Laboratory Data of HCV Patients: Cross Sectional Study

Abstract

Potential relationship of vitamin D, vitamin D receptor (VDR), and vitamin D binding protein (DBP) have been suggested in the pathophysiology of hepatitis C virus (HCV) infection. The aim of this observational study is to determine vitamin D levels, and VDR and DBP genetic polymorphism according demographic and laboratory data in chronic HCV patients (CHC).A total of 148 CHC patients gave serum samples for testing 25-hydroxyvitamin D (25 (OH)D) level by immunochemiluminometric assay (<20 ng/mL defined as deficient) and donated blood samples to allelic discrimination analysis using TaqMan assays. Analyzed single nucleotide polymorphisms (SNPs) were: VDR-rs7975232 (ApaI) C>A, rs731236 A>G (TaqI), rs1544410 C>T (BsmI), rs10735810 T>C (FokI) and carrier globulin/binding protein (GC)-rs4588 and rs7041 and the haplotype bAt [CCA]. Hepatic fibrosis was assessed using Fib-4 and Forns index.Eighty-two (54.40%) patients demonstrated deficiency of vitamin D and this was associated to AST (P = .019 [CI: 1.003-1.034]), total cholesterol (P = .038 [CI: 1.004-1.164]), fibrosis grade (P < .001 [CI: 0.000-0.844]), and FokI (P = .028) allele T presence. Association was found between VDR polymorphism and fibrosis (BsmI andTaqI), triglycerides (TaqI), and HDL (FokI). DBP polymorphism was associated to HCV genotype (GC rs7041), previous HCV treatment, and GGT (GC rs4588).In conclusion, low frequency of vitamin D deficiency was found, but VDR polymorphisms were frequently associated to fibrosis grade suggesting that they could be used as disease evaluation markers to understand the mechanisms underlying the virus-host interaction.

Citing Articles

Evaluation and Comparison of Serum Vitamin D Levels between Injection Drug Users with and without Chronic Hepatitis C Infection in Hamadan-Iran.

Eini P, Hatami M, Eini P, Poorolajal J Maedica (Bucur). 2023; 18(3):437-441.

PMID: 38023763 PMC: 10674129. DOI: 10.26574/maedica.2023.18.3.437.


Association between vitamin D receptor gene polymorphisms and fibrosis susceptibility in Greek patients with HCV infection.

Beka A, Papadopoulos V, Mylopoulou T, Panopoulou M, Karakasiliotis I, Mavromara P Germs. 2023; 12(3):384-393.

PMID: 37680672 PMC: 10482479. DOI: 10.18683/germs.2022.1342.


The Influence of Single Nucleotide Polymorphisms on Vitamin D Receptor Protein Levels and Function in Chronic Liver Disease.

Tourkochristou E, Tsounis E, Tzoupis H, Aggeletopoulou I, Tsintoni A, Lourida T Int J Mol Sci. 2023; 24(14).

PMID: 37511164 PMC: 10380285. DOI: 10.3390/ijms241411404.


The role of vitamin D receptor polymorphisms in the course of chronic hepatitis C infection.

Tsounis E, Tourkochristou E, Sapsani A, Aggeletopoulou I, Lourida T, Zisimopoulos K Ann Gastroenterol. 2022; 35(2):203-212.

PMID: 35479594 PMC: 8922255. DOI: 10.20524/aog.2022.0697.


Vitamin-D Binding Protein Gene Polymorphisms and Serum 25-Hydroxyvitamin-D in a Turkish Population.

Batur L, Ozaydin A, Mavis M, Gursu G, Harbige L, Hekim N Metabolites. 2021; 11(10).

PMID: 34677411 PMC: 8537126. DOI: 10.3390/metabo11100696.


References
1.
Ladero J, Torrejon M, Sanchez-Pobre P, Suarez A, Cuenca F, Orden V . Vitamin D deficiency and vitamin D therapy in chronic hepatitis C. Ann Hepatol. 2013; 12(2):199-204. View

2.
Falleti E, Bitetto D, Fabris C, Fattovich G, Cussigh A, Cmet S . Vitamin D binding protein gene polymorphisms and baseline vitamin D levels as predictors of antiviral response in chronic hepatitis C. Hepatology. 2012; 56(5):1641-50. DOI: 10.1002/hep.25848. View

3.
Hung C, Hu T, Lu S, Chen C, Wang J, Lee C . Association of vitamin D receptor gene polymorphisms with response to peginterferon plus ribavirin in Asian patients with chronic hepatitis C. J Formos Med Assoc. 2016; 115(4):278-83. DOI: 10.1016/j.jfma.2015.11.008. View

4.
Petta S, Camma C, Scazzone C, Tripodo C, Di Marco V, Bono A . Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology. 2010; 51(4):1158-67. DOI: 10.1002/hep.23489. View

5.
Valva P, Rios D, De Matteo E, Preciado M . Chronic hepatitis C virus infection: Serum biomarkers in predicting liver damage. World J Gastroenterol. 2016; 22(4):1367-81. PMC: 4721972. DOI: 10.3748/wjg.v22.i4.1367. View